LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP5 | 1 | C24 | 72 | hr | 868 | 732 | 3486 | 0.2100 | -0.0520 |
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP5 | 2 | C24 | 72 | hr | 868 | 1005 | 3486 | 0.2883 | 0.0523 |
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP5 | 3 | C24 | 72 | hr | 868 | 894 | 3486 | 0.2564 | 0.0099 |
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP6 | 1 | C24 | 72 | hr | 868 | 847 | 3486 | 0.2429 | -0.0081 |
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP6 | 2 | C24 | 72 | hr | 868 | 977 | 3486 | 0.2802 | 0.0416 |
MDA-MB-231 | Mitoxantrone | 0.04 | uM | LJP6 | 3 | C24 | 72 | hr | 868 | 919 | 3486 | 0.2636 | 0.0194 |
MDA-MB-231 | MK2206 | 0.04 | uM | LJP6 | 1 | F06 | 72 | hr | 868 | 3273 | 3486 | 0.9388 | 0.9185 |
MDA-MB-231 | MK2206 | 0.04 | uM | LJP6 | 2 | F06 | 72 | hr | 868 | 3572 | 3486 | 1.0246 | 1.0327 |
MDA-MB-231 | MK2206 | 0.04 | uM | LJP6 | 3 | F06 | 72 | hr | 868 | 3619 | 3486 | 1.0380 | 1.0506 |
MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 1 | A18 | 72 | hr | 868 | 2675 | 3486 | 0.7673 | 0.6901 |
MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 2 | A18 | 72 | hr | 868 | 2403 | 3486 | 0.6893 | 0.5862 |
MDA-MB-231 | Neratinib | 0.04 | uM | LJP5 | 3 | A18 | 72 | hr | 868 | 2886 | 3486 | 0.8278 | 0.7707 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 868 | 2890 | 3486 | 0.8289 | 0.7722 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 868 | 3201 | 3486 | 0.9181 | 0.8910 |
MDA-MB-231 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 868 | 3201 | 3486 | 0.9181 | 0.8910 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 1 | H06 | 72 | hr | 868 | 3135 | 3486 | 0.8992 | 0.8658 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 2 | H06 | 72 | hr | 868 | 4206 | 3486 | 1.2064 | 1.2748 |
MDA-MB-231 | Nintedanib | 0.04 | uM | LJP6 | 3 | H06 | 72 | hr | 868 | 4215 | 3486 | 1.2090 | 1.2783 |
MDA-MB-231 | NU7441 | 0.04 | uM | LJP5 | 1 | C12 | 72 | hr | 868 | 3273 | 3486 | 0.9388 | 0.9185 |
MDA-MB-231 | NU7441 | 0.04 | uM | LJP5 | 2 | C12 | 72 | hr | 868 | 3754 | 3486 | 1.0768 | 1.1022 |
MDA-MB-231 | NU7441 | 0.04 | uM | LJP5 | 3 | C12 | 72 | hr | 868 | 3843 | 3486 | 1.1023 | 1.1362 |
MDA-MB-231 | Dactolisib | 0.04 | uM | LJP5 | 1 | M18 | 72 | hr | 868 | 1938 | 3486 | 0.5559 | 0.4086 |
MDA-MB-231 | Dactolisib | 0.04 | uM | LJP5 | 2 | M18 | 72 | hr | 868 | 2109 | 3486 | 0.6049 | 0.4739 |
MDA-MB-231 | Dactolisib | 0.04 | uM | LJP5 | 3 | M18 | 72 | hr | 868 | 2035 | 3486 | 0.5837 | 0.4457 |
MDA-MB-231 | NVP-TAE684 | 0.04 | uM | LJP6 | 1 | K18 | 72 | hr | 868 | 3350 | 3486 | 0.9609 | 0.9479 |